Imagine if we could use the global experience of the pandemic as a giant map to see how COVID triggers brain diseases like Alzheimer's. This work uses AI to spot patterns in big data and lab tests to find existing drugs that might stop this process. It's like finding a hidden link between two illnesses and then searching a pharmacy for a key that unlocks a cure.
Healthcare systems face a potential wave of dementia and neurodegenerative diseases triggered by COVID-19. There is a lack of personalized tools to assess this risk and a need for faster drug discovery to treat these comorbidities.
An AI-powered recommender system based on qualified biomarkers and a set of cell-based assays for drug repurposing screenings.
If you are a drug discovery firm dealing with high R&D costs for new dementia treatments — this project developed cell-based assays and identified candidate mechanisms that allow for drug repurposing. This reduces the time to find effective treatments by using existing medicines.
If you are a health-tech developer dealing with a lack of personalized risk tools for post-COVID patients — this project developed qualified biomarkers and predictive features. These can be integrated into an AI-powered recommender system for individualized risk assessment.
If you are a clinic dealing with the rising wave of dementia cases after the pandemic — this project developed a model-generated recommender system. This allows for personalized recommendations and better patient stratification based on COVID history.
Based on available project data, there is no specific pricing or cost information provided for the AI recommender system.
The project uses big data and AI/ML technologies designed for population-level analysis, suggesting high scalability for digital health applications.
Based on available project data, the project collaborates with REMEDI4ALL for drug repurposing, but specific licensing terms are not disclosed.
The project specifically analyzes legal and ethical requirements, including GDPR consent for patients with neurodegenerative diseases.
The project period runs until 2027-11-30, with recommendations published at the conclusion.
The consortium is well-balanced for translation, featuring 12 partners across 9 countries. With a 25% industry ratio (including 3 SMEs), there is a clear bridge between the 4 universities and 5 research institutions and the commercial market, coordinated by the applied research powerhouse Fraunhofer.
Contact Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung EV
Contact us to explore licensing opportunities for the AI-powered recommender system.
